DFTX Definium Therapeutics, Inc.
DFTX Definium Therapeutics, Inc.
Healthcare · Biotechnology
Market read
Scan convergence 1 scan as of 2026-10-23 1 neutral converging
POC $12.91 · VWAP $27.81 · +28.3% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Cluster CEO, CFO + 3 others sold $2.3M, Sep 29
Coverage
2 watchlists
DFTX Price Structure
Loading timeframes…
Peers
Every watchlist DFTX belongs to, members best 30-day change first — DFTX highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@biotech-scan
@monster-discoveries
Decision history
1 scored call · newest first · projection
How to read this: Positive 30-day excess supports an enter call. For pass, avoid, sell, or exit calls, a positive number means the name kept rising after the call.
Reported the quarter ending 2026-06-30: diluted EPS -$1.44, net income -$159M (SEC filing). Across the print the stock moved +3.9% (close before → first close after).
full note →Against street estimates
How DFTX's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. A consensus out of line with the name's earlier estimates (opposite sign to all of them and over 3x their size) is not graded. EPS only.
DFTX research tape
80 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.